PHARMACY

FDA approves Akorn’s generic Voltaren gel

BY Sandra Levy

Specialty generic company Akorn has received the Food and Drug Administration’s clearance for its generic Voltaren gel (diclofenac sodium topical gel 1%).

Diclofenac sodium topical gel is indicated for the relief of pain of osteoarthritis of joints amenable to topical treatment, including knees and hands.

The product had a market value of approximately $357 million for the 12 months ended September 2018, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

What area is your company focused most on in 2019?
  • Add your answer